Hims & Hers Health Inc. (HIMS) shares plummeted 26.2% during Monday's early trading session. The company has abandoned its plan to sell compounded semaglutide tablets, citing regulatory scrutiny from the FDA and potential legal challenges. Concurrently, shares of Novo-Nordisk A/S (NVO), the maker of the branded drug Wegovy, saw an increase in their stock price.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.